These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19734850)

  • 1. Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer.
    Jögi A; Brennan DJ; Rydén L; Magnusson K; Fernö M; Stål O; Borgquist S; Uhlen M; Landberg G; Påhlman S; Pontén F; Jirström K
    Mod Pathol; 2009 Dec; 22(12):1564-74. PubMed ID: 19734850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.
    Rexhepaj E; Jirstrom K; O'Connor DP; O'Brien SL; Landberg G; Duffy MJ; Brennan DJ; Gallagher WM
    BMC Cancer; 2010 Nov; 10():639. PubMed ID: 21092276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer.
    Migliaccio I; Wu MF; Gutierrez C; Malorni L; Mohsin SK; Allred DC; Hilsenbeck SG; Osborne CK; Weiss H; Lee AV
    Breast Cancer Res Treat; 2010 Oct; 123(3):651-60. PubMed ID: 19924529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High RNA-Binding Motif Protein 3 (RBM3) Expression is Independently Associated with Prolonged Overall Survival in Intestinal-Type Gastric Cancer.
    Ye F; Jin P; Cai X; Cai P; Cai H
    Med Sci Monit; 2017 Dec; 23():6033-6041. PubMed ID: 29263314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer.
    Hjelm B; Brennan DJ; Zendehrokh N; Eberhard J; Nodin B; Gaber A; Pontén F; Johannesson H; Smaragdi K; Frantz C; Hober S; Johnson LB; Påhlman S; Jirström K; Uhlen M
    Proteomics Clin Appl; 2011 Dec; 5(11-12):624-35. PubMed ID: 21956899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.
    Habashy HO; Powe DG; Staka CM; Rakha EA; Ball G; Green AR; Aleskandarany M; Paish EC; Douglas Macmillan R; Nicholson RI; Ellis IO; Gee JM
    Breast Cancer Res Treat; 2010 Jan; 119(2):283-93. PubMed ID: 19238537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer.
    Campbell EJ; McDuff E; Tatarov O; Tovey S; Brunton V; Cooke TG; Edwards J
    Br J Cancer; 2008 Dec; 99(11):1769-74. PubMed ID: 19018258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.
    Sjöström M; Hartman L; Grabau D; Fornander T; Malmström P; Nordenskjöld B; Sgroi DC; Skoog L; Stål O; Leeb-Lundberg LM; Fernö M
    Breast Cancer Res Treat; 2014 May; 145(1):61-71. PubMed ID: 24715381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
    Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
    JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
    Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
    J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
    Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
    Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer.
    O Leary PC; Penny SA; Dolan RT; Kelly CM; Madden SF; Rexhepaj E; Brennan DJ; McCann AH; Pontén F; Uhlén M; Zagozdzon R; Duffy MJ; Kell MR; Jirström K; Gallagher WM
    BMC Cancer; 2013 Apr; 13():175. PubMed ID: 23547718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic significance of Wnt-5a expression in primary breast cancer is extended to premenopausal women.
    Sand-Dejmek J; Ehrnström R; Berglund P; Andersson T; Ryden L
    PLoS One; 2013; 8(8):e70890. PubMed ID: 23990917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
    Bago-Horvath Z; Rudas M; Dubsky P; Jakesz R; Singer CF; Kemmerling R; Greil R; Jelen A; Böhm G; Jasarevic Z; Haid A; Gruber C; Pöstlberger S; Filipits M; Gnant M;
    Clin Cancer Res; 2011 Dec; 17(24):7828-34. PubMed ID: 21998336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-X-C ligand 10 and C-X-C receptor 3 status can predict tamoxifen treatment response in breast cancer patients.
    Hilborn E; Sivik T; Fornander T; Stål O; Nordenskjöld B; Jansson A
    Breast Cancer Res Treat; 2014 May; 145(1):73-82. PubMed ID: 24715380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen.
    Brennan DJ; Laursen H; O'Connor DP; Borgquist S; Uhlen M; Gallagher WM; Pontén F; Millikan RC; Rydén L; Jirström K
    Breast Cancer Res; 2011 Jan; 13(1):R12. PubMed ID: 21281480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.
    Liu J; Prager-van der Smissen WJ; Look MP; Sieuwerts AM; Smid M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
    Cancer Lett; 2016 Jun; 376(1):104-9. PubMed ID: 27018307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials.
    Ross DT; Kim CY; Tang G; Bohn OL; Beck RA; Ring BZ; Seitz RS; Paik S; Costantino JP; Wolmark N
    Clin Cancer Res; 2008 Oct; 14(20):6602-9. PubMed ID: 18927301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression.
    Jonsson L; Gaber A; Ulmert D; Uhlén M; Bjartell A; Jirström K
    Diagn Pathol; 2011 Sep; 6():91. PubMed ID: 21955582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.